AI Article Synopsis
- Somatostatin analogues like octreotide and lanreotide are used to treat enterocutaneous fistulas.
- A patient experienced severe hyperglycemia after a single dose of lanreotide, despite having no prior history of diabetes and being stable on octreotide.
- The management of the patient's hyperglycemia during parenteral nutrition is discussed in the report.
Article Abstract
Somatostatin analogues, suchas octreotide and lanreotide, are commonly used in the management of enterocutaneous fistula. We report a case of severe and prolonged hyperglycemia that occurred in a patient after receiving a one-time dose of lanreotide, who had previously been stable on octreotide and did not have a history of diabetes mellitus. Management of the patient's hyperglycemia while receiving parenteral nutrition is described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ncp.10757 | DOI Listing |
Publication Analysis
Top Keywords
octreotide lanreotide
8
enterocutaneous fistula
8
receiving parenteral
8
parenteral nutrition
8
severe hyperglycemia
4
hyperglycemia transition
4
transition octreotide
4
lanreotide patient
4
patient enterocutaneous
4
fistula receiving
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!